Effects of chronic nitric oxide synthase inhibition on the cardiovascular responses to cannabinoids in vivo and in vitro

British Journal of Pharmacology

Volumn 150, Issue 5, 2007, Pages 662-671

  Wheal, A J ^a   Bennett, T ^a   Randall, M D ^a   Gardiner, S M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anandamide; Cannabinoids; Hypertension; Nitric oxide synthase; Regional haemodynamics

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; DRINKING WATER; METHANANDAMIDE; N(G) NITROARGININE METHYL ESTER;

ANIMAL EXPERIMENT; ARTERY PERFUSION; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DRUG EFFECT; ENZYME INHIBITION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ARACHIDONIC ACIDS; BENZOXAZINES; BLOOD PRESSURE; CANNABINOIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEART RATE; HYPERTENSION; MALE; MESENTERIC ARTERIES; MORPHOLINES; MUSCLE, SKELETAL; NAPHTHALENES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RENAL CIRCULATION; SPLANCHNIC CIRCULATION; TIME FACTORS; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATION; VASODILATOR AGENTS;

EID: 33847678029     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707136     Document Type: Article

References (49)

1. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J et al. (2004). Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110: 1996-2002.
2. Baylis C, Mitruka B, Deng A (1992). Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281.
3. Chaytor AT, Martin PE, Evans WH, Randall MD, Griffith TM (1999). The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol 520: 539-550.
4. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK et al. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100: 1538-1546.
5. Dunn WR, Gardiner SM (1995). No evidence for vascular remodelling during hypertension induced by chronic inhibition of nitric oxide synthase in Brattleboro rats. J Hypertens 13: 849-857.
6. Ferro A, Coash M, Yamamoto T, Rob J, Ji Y, Queen L (2004). Nitric oxide-dependent beta2-adrenergic dilatation of rat aorta is mediated through activation of both protein kinase A and Akt. Br J Pharmacol 143: 397-403.
7. Gardiner SM, Compton AM, Bennett T, Palmer RM, Moncada S (1990). Regional haemodynamic changes during oral ingestion of NG-monomethyl-L-arginine or NG-nitro-L-arginine methyl ester in conscious Brattleboro rats. Br J Pharmacol 101: 10-12.
8. Gardiner SM, Dunn WR, Bennett T (1999). Chronic nitric oxide inhibition model six years on. Hypertension 34: e4.
9. Gardiner SM, Kemp PA, Bennett T (1991). Effects of NG-nitro-L- arginine methyl ester on vasodilator responses to acetylcholine, 5′-N-ethylcarboxamidoadenosine or salbutamol in conscious rats. Br J Pharmacol 103: 1725-1732.
10. Gardiner SM, March JE, Kemp PA, Bennett T (2002a). Complex regional haemodynamic effects of anandamide in conscious rats. Br J Pharmacol 135: 1889-1896.
11. 1 receptor antagonist, AM 251, on the regional haemodynamic effects of WIN-55212-2 or HU 210 in conscious rats. Br J Pharmacol 136: 581-587.
12. Harris D, McCulloch AI, Kendall DA, Randall MD (2002). Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J Physiol 539: 893-902.
13. Howlett AC, Mukhopadhyay S (2000). Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids 108: 53-70.
14. 2 receptors. Proc Natl Acad Sci USA 96: 14136-14141.
15. Jarrahian A, Hillard CJ (1997). Arachidonylethanolamide (anandamide) binds with low affinity to dihydropyridine binding sites in brain membranes. Prostaglandins Leukot Essent Fatty Acids 57: 551-554.
16. Johnson DE, Heald SL, Dally RD, Janis RA (1993). Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Prostaglandins Leukot Essent Fatty Acids 48: 429-437.
17. Kunos G, Jarai Z, Batkai S, Goparaju SK, Ishac EJ, Liu J et al. (2000). Endocannabinoids as cardiovascular modulators. Chem Phys Lipids 108: 159-168.
18. Kwolek G, Zakrzeska A, Schlicker E, Gothert M, Godlewski G, Malinowska B (2005). Central and peripheral components of the pressor effect of anandamide in urethane-anaesthetized rats. Br J Pharmacol 145: 567-575.
19. Lake KD, Martin BR, Kunos G, Varga K (1997). Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29: 1204-1210.
20. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA et al. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404.
21. Li J, Kaminski NE, Wang DH (2003). Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor. Hypertension 41: 757-762.
22. Lopez-Miranda V, Herradon E, Dannert MT, Alsasua A, Martin MI (2004). Anandamide vehicles: a comparative study. Eur J Pharmacol 505: 151-161.
23. MacDonald A, McLean M, MacAulay L, Shaw AM (1999). Effects of propranolol and L-NAME on beta-adrenoceptor-mediated relaxation in rat carotid artery. J Auton Pharmacol 19: 145-149.
24. 1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 364: 562-569.
25. Mendizábal VE, Orliac ML, Adler-Graschinsky E (2001). Long-term inhibition of nitric oxide synthase potentiates effects of anandamide in the rat mesenteric bed. Eur J Pharmacol 427: 251-262.
26. Mulvany MJ, Halpern W (1977). Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41: 19-26.
27. O'Sullivan SE, Kendall DA, Randall MD (2004). Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br J Pharmacol 142: 435-442.
28. Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK et al. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63: 699-705.
29. Pacher P, Batkai S, Kunos G (2004). Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol 558: 647-657.
30. Randall MD, Alexander SP, Bennett T, Boyd EA, Fry JR, Gardiner SM et al. (1996). An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun 229: 114-120.
31. Randall MD, Kendall DA, O'Sullivan S (2004). The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142: 20-26.
32. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R (1992). Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20: 298-303.
33. Rösch S, Ramer R, Brune K, Hinz B (2006). R(+)-methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells. J Pharmacol Exp Ther 316: 1219-1228.
34. Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ et al. (2001). Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 132: 631-640.
35. Scrogin KE, Hatton DC, Chi Y, Luft FC (1998). Chronic nitric oxide inhibition with L-NAME: effects on autonomic control of the cardiovascular system. Am J Physiol 274: R367-R374.
36. Smith PJ, McQueen DS (2001). Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat. Br J Pharmacol 134: 655-663.
37. Souza HC, Ballejo G, Salgado MC, Da Silva VJ, Salgado HC (2001). Cardiac sympathetic overactivity and decreased baroreflex sensitivity in L-NAME hypertensive rats. Am J Physiol Heart Circ Physiol 280: H844-H850.
38. Tep-Areenan P, March JE, Kemp PA, Randall MD, Kendall DA, Bennett T et al. (2002). Effects of chronic in vivo treatment with nitric oxide synthase inhibitor on vasorelaxant responses to anandamide in rat isolated arteries. Br J Pharmacol 137: 55P.
39. Varga K, Lake K, Martin BR, Kunos G (1995). Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 278: 279-283.
40. Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G (1996). Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 28: 682-686.
41. Wagner JA, Varga K, Jarai Z, Kunos G (1999). Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33: 429-434.
42. Wakefield ID, March JE, Kemp PA, Valentin JP, Bennett T, Gardiner SM (2003). Comparative regional haemodynamic effects of the nitric oxide synthase inhibitors, S-methyl-L-thiocitrulline and L-NAME, in conscious rats. Br J Pharmacol 139: 1235-1243.
43. Wang Y, Kaminski NE, Wang DH (2005). VR1-mediated depressor effects during high-salt intake: role of anandamide. Hypertension 46: 986-991.
44. White R, Hiley CR (1997). A comparison of EDHF-mediated and anandamide-induced relaxations in the rat mesenteric artery. Br J Pharmacol 122: 1573-1584.
45. White R, Hiley CR (1998). The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br J Pharmacol 125: 689-696.
46. Willoughby KA, Moore SF, Martin BR, Ellis EF (1997). The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282: 243-247.
47. Yang YY, Lin HC, Huang YT, Lee TY, Hou MC, Wang YW et al. (2006). Roles of anandamide in the hepatic microcirculation in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol 290: G328-G334.
48. Zatz R, Baylis C (1998). Chronic nitric oxide inhibition model six years on. Hypertension 32: 958-964.
49. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452-457.